Pharmacokinetics and pharmacodynamics of drugs for Nontuberculous Mycobacterial diseases in Dutch patients - PK and PD of drugs for Nontuberculous Mycobacterial diseases

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 26 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•Currently treated for NTM infection or recently diagnosed with NTM infection starting treatment at ULC Dekkerswald, Groesbeek, or Centre for Revalidation Beatrixoord, Haren, the Netherlands.
•Diagnosis and treatment according to ATS criteria for NTM infections. Patients with pulmonary (eventually with extrapulmonary localizations) NTM infections are eligible.
•Treated with at least rifampicin and ethambutol and optionally with claritromycin or azitromycin on a daily basis.
•Age >=18 years.
•Patient has been using drugs for at least two weeks when steady state concentrations of rifampicin and azithromycin is expected.
•Informed consent has been signed.

•The medical state of the patients does not allow inclusion according to the physician in attendance.
•The patients* clinical parameters urge immediate cessation of drugs.
•The patient is pregnant.
•Significant hepatic or renal dysfunction
•Patients with cystic fibrosis, since these show deviating pharmacokinetics for many drugs.
•Patients with HIV infection

发起方

niversitair Medisch Centrum Sint Radboud